WHAT A CONFERENCE! This was the brain child of Adrienne Dorrance and executed to perfection by an army of people including the amazing folks at Sundance Resort. Thank you to all our incredible attendees, speakers, and sponsors. We couldn’t have done this without all of you! #WBC2025

You made my day James !!! Thank you !!!

Looking forward to kicking off the oral abstract session in AML with Gail Roboz presenting data on oral Decitabine-Cedazuridine and Venetoclax in newly Dx older AML pts European Hematology Association #EHA25

Impressive results of 7+3 + Ziftomenib in newly diagnosed AML patients with NPM1m or KMT2Ar presented by Harry Erba. We are embarking on a new era of menin inhibitors in combination with frontline therapy in newly Dx AML w/ NPM1m or KMT2Ar. European Hematology Association #EHA25

Great talk by ⁦Joshua Zeidner MD⁩ at #EHA2025 on adding revumenib to ven/aza in up front AML patients. Great early outcomes, really promising!

Happy to share our newest work out today in BCD evaluating disease classification and prognosis in the “world of myeloid malignancies”! Wonderful collaboration with Sanam Loghavi, MD صنم لغوی 🔬🧬 Elli Papaemmanuil, PhD Elsa Bernard and colleagues.

Awesome work congratulations!!

Sanam Loghavi, MD صنم لغوی 🔬🧬 Elli Papaemmanuil, PhD Thank you, Sanam Loghavi, MD صنم لغوی 🔬🧬 and Elli Papaemmanuil, PhD for the opportunity. The best part is working with all the individuals who collaborated on this project.

When a CT scan revealed a mass on his bladder, CU Boulder 🦬 football coach Deion "Coach Prime" Sanders was referred to #CUAnschutz – a national leader in #bladdercancer care – where he met with Janet Kukreja, MD, director of urologic oncology at CU Cancer Center and uchealth.

#OnlineFirst Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study brnw.ch/21wUvxr

#IntheSpotlight A FABulous Couple: Adding PHENotype to GENotype Improves HMA/VEN Response Prediction in AML brnw.ch/21wUNVw

Dr. Andrew Kent from CU Anschutz Division of Hematology and CU Cancer Center is leading a trial testing if mitoxantrone can help AML patients resistant to current treatments. This could change leukemia care. 🌟 bit.ly/40WelTC #CancerResearch #MedTwitter

Dr. Brad Haverkos CU Anschutz Division of Hematology contributed to a CIBMTR study of CD19 CAR-T for PMBCL, now published AmericanJournalofHematology. Two-year PFS 59% and two-year OS 81%, with two-year cumulative incidence of relapse at 36%. #lymsm #tcellrx

ASH elections ballots were sent out today. I am voting for Mikkael A. Sekeres MD, MS for councilor! Mikkael is a tremendous mentor to so many of us, and an invaluable advocate for all things Hematology. The future of ASH will be in great hands with his leadership.

Totally humbled by your generosity Daniel Pollyea, especially coming from someone as inspiring as you! 😊🙏

#BloodCancerAwarenessMonth: CU Cancer Center member Christine McMahon, MD, discusses the various types of blood cancers treated at the center. You can learn more about blood cancer here: bit.ly/38t02tP

The #NashvilleHeme26 Poster Competition is officially open! Share your research, get recognized, and join leaders in hematology at the 2-day CE-accredited conference. Abstracts are due October 10 — don’t miss it: hubs.la/Q03GL4qB0 #HemeOnc #HematologyResearch #OncTwitter

Welcome new faculty Dr. Thomas Kartika to CU Hematology and to *the most gorgeous* of all the United States: COLORADO. 🌞🌄❄️🍂We are happy you are here!

☀️ Sunshine State Sunday Spotlight! Join us in Orlando before #ASH25 for Medical Crossfire®: Experts Debate AML🔥 📅 Dec 5, 2025 | 📍 Orlando, FL FLT3, IDH1/2, KMT2Ar, NPM1, secondary AML & more! Register now. tinyurl.com/bd72vuhh Amer Zeidan MBBS,MHS ‏عامر زيدان Naval Daver, M.D. Daniel Pollyea

Denver Denver Broncos passing game specialist Zack Grossi (Zack Grossi) is cancer-free after undergoing treatment for a yolk sac tumor with providers at the CU Cancer Center ⬇️ news.cuanschutz.edu/cancer-center/…